Screener
Edgewise Therapeutics, Inc. EWTX Business Segments — Contracted Research Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept ewtx:ContractedResearchExpense.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Contracted research expense | $23,942 | $21,298 |
| Personnel expense | 14,725 | 10,624 |
| Stock-based compensation expense | 8,715 | 9,059 |
| Other segment expense(a) | 6,196 | 4,464 |
| Depreciation | 537 | 514 |
| Segment net loss | (54,115) | (45,959) |
| Reconciliation of net loss |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s business segments — contracted research expense?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — contracted research expense of $23.94M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — contracted research expense changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — contracted research expense increased by 12.4% year-over-year, from $21.3M to $23.94M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — contracted research expense?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — contracted research expense has grown at a 23.7% compound annual growth rate (CAGR), from $57.5M to $87.99M.
- What does business segments — contracted research expense mean?
- Represents the costs incurred by the company for outsourced research and development activities, including payments to contract research organizations (CROs) and external laboratories. This metric reflects the company's reliance on external partners to accelerate clinical trials and drug discovery programs. Monitoring this helps investors assess the intensity of R&D outsourcing strategies.
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — contracted research expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude